Changing costs and the impact on RSV prophylaxis

Journal of Medical Economics

Volumn 13, Issue 4, 2010, Pages 705-708

  Smart, Kelly A ^a,b   Paes, Bosco A ^c   Lanctt, Krista L ^a,b  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c MCMASTER CHILDREN S HOSPITAL   (Canada)

Author keywords

Cost analysis; Cost effectiveness analysis; Palivizumab; Respiratory syncytial virus

Indexed keywords

PALIVIZUMAB;

ARTICLE; COST EFFECTIVENESS ANALYSIS; DRUG COST; GESTATIONAL AGE; HEALTH CARE COST; HUMAN; INFANT; NEWBORN INTENSIVE CARE; PREMATURITY; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY SYNCYTIAL VIRUS INFECTION; RISK ASSESSMENT; RISK FACTOR;

ANTIBODIES, MONOCLONAL; ANTIVIRAL AGENTS; CANADA; CHEMOPREVENTION; COST-BENEFIT ANALYSIS; COSTS AND COST ANALYSIS; GESTATIONAL AGE; HUMANS; INFANT, NEWBORN; MODELS, ECONOMIC; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS;

EID: 78650045933     PISSN: 13696998     EISSN: None     Source Type: Journal    
DOI: 10.3111/13696998.2010.535577     Document Type: Article

References (16)

1. Leader S, Kohlhase K. Recent trends in severe respiratory syncytial virus (RSV) among US infants, 1997 to 2000. J Pediatr 2003;143:S127-132
2. Impact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from syncytial virus infection in high-risk infants. Pediatrics 1998;102:531-537
3. Smart KA, Paes BA, Lanctôt KL. The cost-effectiveness of palivizumab: a systematic review of the evidence. J Med Econ 2010;13:453-463
4. Nuijten MJC, Wittenberg W, Lebmeier M. Cost effectiveness of palivizumab for respiratory syncytial virus prophylaxis in high-risk children. Pharmacoeconomics 2007;25:55-71
5. Joffe S, Ray GT, Escobar GJ, et al. Cost-effectiveness of respiratory syncytial virus prophylaxis among preterm infants. Pediatrics 1999;107:419-427
6. Thomson-Healthcare. Redbooktm for Windows. Vol 57, 2010
7. Krilov LR, Palazzi DL, Fernandes AW, et al. Prevalence of respiratory syncytial virus (RSV) risk factors and cost implications of immunoprophylaxis to infants 32 to 35 weeks gestation for health plans in the United States. Value Health 2010;13:77-86
8. Committee on Infectious Diseases. From the American Academy of Pediatrics: policy statements - modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections. Pediatrics 2009;14:521-526
9. Lanctôt KL, Masoud S, Paes BA, et al. The cost-effectiveness of palivizumab for respiratory syncytial virus prophylaxis in premature infants with a gestational age of 32-35 weeks: a Canadian-based analysis. Curr Med Res Opin 2008;24:3223-3237
10. Sampalis JS, Langley J, Carbonell-Estrany X, et al. Development and validation of a risk scoring tool to predict respiratory syncytial virus hospitalization in premature infants born at 33 through 35 completed weeks of gestation. Med Decis Making 2008;28:471-480
11. Ontario Case Costing Initiative (OCCI). Acute inpatient database. Available at: http://www.occp.com/ [Last accessed 15 August, 2010]
12. Health Canada. Schedule A 2010/11 Ontario Hospital interprovincial per diem rates for inpatient services (effective April 1, 2010). Available at: http://www.health.gov.on.ca/English/Providers/Program/OHIP/Bulletins/ Na-38/Na-38-20100511-Att1.Pdf [Last accessed 15 August, 2010]
13. Ontario Ministry of Health and Long Term Care. Schedule of benefits - physician services under the Health Insurance Act (effective July 1, 2010), 2010
14. Kramer MS, Demissie K, Yang H, et al. The contribution of mild and moderate preterm birth to infant mortality. JAMA 2000;284:843-849
15. Samson L. Canadian Paediatric Society, Infectious Diseases and Immunization Committee. J Paediatr Child Health 2009;14:521-526
16. Sampalis JS. Morbidity and mortality after RSV-associated hospitalizations among premature Canadian infants. J Pediatr 2003;143:S150-156